Table 2

Pediatric AIS patients with ICH during ACT

Case no.Age, ySexPre-existing conditionPre-existing ICHTreatment at time of ICHInterval event to ICHECASS gradeChange over timeClinical presentation at time of ICHRisk factor for bleedClinical Outcome
15.7 Acute myeloid leukemia, Antiphopholipid syndrome None UFH HI1 Progression, remained HI1 Asymptomatic then coma due to recurrent AIS and ICH Abnormal lab: PLT-32, anti–Xa-0.81, HgB-85 APLA ayndrome Died (fatal catastrophic APLA syndrome with recurrent emboli and bleeds) 
10.4 CHD None Warfarin 10 HI2 Regression, HI1 Asymptomatic  Died (cardiac) 
11.5 CHD-S/P heart transplant. None LMWH 20   Asymptomatic  Mild neurological deficit 
11 CHD None UFH and ASA HI1  Asymptomatic  Severe neurological deficit 
5.8 Vasculitis None UFH   Asymptomatic  Severe neurological deficit 
1.5 CHD None LMWH and Warfarin HI2  Asymptomatic  Severe neurological deficit 
14.8 Hyperlipidemia None LMWH 12 HI2  Asymptomatic  Normal 
2.2 CHD after Fontan surgery Yes LMWH 26 PH2  Asymptomatic Abnormal lab: INR-3 Severe neurological deficit 
ECASS HI1 
2.6 Post varicella vaccine None LMWH 13 HI1  Asymptomatic  Moderate neurological deficit 
10 7.9 Post varicella None UFH   Facial drop and aphasia  Mild neurological deficit 
11 1.4 Moya-moya disease None UFH and ASA HI1 Progression, HI1 Focal seizure and irritability  Severe neurological deficit 
12 2.9 CHD after catheterization None LMWH and Warfarin 15 HI1  Irritability  Died (cardiac) 
13 14 CHD after catheterization None UFH HI1  Loss of consciousness/coma  Moderate neurological deficit 
14 8.9 Minor trauma None LMWH 10 HI1  Headache and vomiting  Severe neurological deficit 
Case no.Age, ySexPre-existing conditionPre-existing ICHTreatment at time of ICHInterval event to ICHECASS gradeChange over timeClinical presentation at time of ICHRisk factor for bleedClinical Outcome
15.7 Acute myeloid leukemia, Antiphopholipid syndrome None UFH HI1 Progression, remained HI1 Asymptomatic then coma due to recurrent AIS and ICH Abnormal lab: PLT-32, anti–Xa-0.81, HgB-85 APLA ayndrome Died (fatal catastrophic APLA syndrome with recurrent emboli and bleeds) 
10.4 CHD None Warfarin 10 HI2 Regression, HI1 Asymptomatic  Died (cardiac) 
11.5 CHD-S/P heart transplant. None LMWH 20   Asymptomatic  Mild neurological deficit 
11 CHD None UFH and ASA HI1  Asymptomatic  Severe neurological deficit 
5.8 Vasculitis None UFH   Asymptomatic  Severe neurological deficit 
1.5 CHD None LMWH and Warfarin HI2  Asymptomatic  Severe neurological deficit 
14.8 Hyperlipidemia None LMWH 12 HI2  Asymptomatic  Normal 
2.2 CHD after Fontan surgery Yes LMWH 26 PH2  Asymptomatic Abnormal lab: INR-3 Severe neurological deficit 
ECASS HI1 
2.6 Post varicella vaccine None LMWH 13 HI1  Asymptomatic  Moderate neurological deficit 
10 7.9 Post varicella None UFH   Facial drop and aphasia  Mild neurological deficit 
11 1.4 Moya-moya disease None UFH and ASA HI1 Progression, HI1 Focal seizure and irritability  Severe neurological deficit 
12 2.9 CHD after catheterization None LMWH and Warfarin 15 HI1  Irritability  Died (cardiac) 
13 14 CHD after catheterization None UFH HI1  Loss of consciousness/coma  Moderate neurological deficit 
14 8.9 Minor trauma None LMWH 10 HI1  Headache and vomiting  Severe neurological deficit 

M indicates male; and F, female.

*

Case 8 ACT despite initial ICH administered ACT for cardiac indication (shunt). Patient also had history of femoral vein thrombosis.

Close Modal

or Create an Account

Close Modal
Close Modal